Molecular basis of human neutrophil antigen 2 (HNA-2) expression

Behnaz Bayat
Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany

HNA-2 is a neutrophil-specific antigen located on GPI-anchored glycoprotein CD177. HNA-2 is absent from the neutrophil surface of 3–5% of normal individuals, known as HNA-2 null individuals. The exposure of HNA-2 null individuals to HNA-2-positive neutrophils during pregnancy, transfusion or transplantation induces immunization against HNA-2 and production of isoantibodies. These isoantibodies are involved in the mechanism of neonatal alloimmune neutropenia (NAIN), transfusion-related acute lung injury (TRALI) and graft rejection. The presence of CD177 on a neutrophil surface of HNA-2-positive individuals follows a bimodal expression that categorizes the circulating neutrophils into HNA-2-positive and HNA-2-negative subsets. The lack of HNA-2 (in HNA-2 null individuals) is associated with the presence of a missense mutation, CD177 c.787A>T in exon 7 (Lysine 263 Stop) of the CD177 gene. This mutation alone or in combination with CD177 c.997delG has been introduced as the main reason for the absence of CD177 in HNA-2 null individuals. A pseudogene (CD177 P1) is located downstream of the CD177 gene. The conversion of exon 7 of CD177 P1 into CD177 is responsible for the generation of the CD177 c.787A>T missense mutation. Genotyping has identified HNA-2 null individuals that are heterozygous for the CD177 c.787A>T mutation without CD177 c.997delG, indicating the presence of a complementary mechanism regulating CD177 expression. In HNA-2 null individuals and those with atypical CD177 expression, a CD177 c.1291G>A polymorphism in combination with CD177 c.787A>T has been recently described. Altogether, these data indicate a complex compound mechanism for the regulation of CD177 expression on the neutrophil surface. This manuscript will summarize recent findings on CD177 expression and highlights the CD177 functions on neutrophil surface.

Key words: alloimmunisation, expression, CD177, genotyping, human neutrophil antigen 2 (HNA-2).

Introduction

The human neutrophil antigen 2 (HNA-2) epitopes are located on the CD177 protein, known as NB1. CD177 is a glycosyl-phosphatidylinositol (GPI)-anchored glycoprotein that is exclusively expressed by neutrophils. HNA-2 was first identified in 1971 in a case of alloimmune neutropenia [1]. The absence of HNA-2 on the neutrophil surface of 3–5% of individuals in the healthy population is the reason for the iso-immunization against this protein upon exposure to HNA-2-positive cells (during pregnancy, transfusion or transplantation) [1,2].

Isoantibodies directed against HNA-2 are involved in transfusion-related acute lung injury (TRALI), neonatal alloimmune neutropenia (NAIN) and graft rejection [1,2]. CD177 is detectable during terminal neutrophil differentiation and peaked in band cells [3]. The CD177 expression on the neutrophils of adult individuals follows a bimodal
expression that generates CD177+ and CD177- subpopulations and remains constant in time.

The function of CD177 is mainly unknown; the trans-interaction of CD177 with PECAM-1 on the endothelial surface was previously proposed [4]. This heterophilic interaction leads to endothelial junction instability and is therefore involved in neutrophil transmigration through endothelial cells [5]. In the cis-interaction, CD177 interacts with proteinase 3 (PR3), a major antigen for the antineutrophil cytoplasmic autoantibody (ANCA). The neutrophil subpopulation expressing PR3 (PR3(pos subpopulation) is identical to the CD177(pos subpopulation) [6,7]. PR3 interaction with CD177 is mediated by a hydrophobic patch on the C-terminus of the PR3 protein [8]. ANCA-induced neutrophil activation is the result of CD177/PR3 interaction with the CD11b/CD18 (Mac-1) complex on the neutrophil surface [9]. Co-localization of CD177/PR3 with CD11b/CD18 on the neutrophil surface provides this complex with signalling transduction abilities, therefore allowing its participation in neutrophil activation and degranulation in response to ANCA binding.

The current review aims to summarize recent findings on CD177 expression and functions and highlights the genetic regulation of CD177 expression on the neutrophil surface.

**HNA-2 expression**

The HNA-2 epitope is located on glycoprotein CD177, a GPI-anchored glycoprotein which belongs to the LY-6 family, and contains two cysteine-rich domains. Investigation using alloantibodies and monoclonal antibodies has identified CD177 as a protein of 58–64 kDa on the surface of neutrophils and also in secondary granules [10]. CD177 appears on the surface of myelocytes, metamyelocytes and neutrophils [11].

On the neutrophil surface of 3-5% of normal individuals, HNA-2 is not detectable; these are known as HNA-2null individuals. The HNA-2null individuals are healthy, with normal neutrophil function, suggesting the possible presence of an alternative protein that duplicates the function of HNA-2 on neutrophils [12]. In HNA-2-positive individuals, the bimodal expression of HNA-2 divides neutrophils into two HNA-2pos and HNA-2neg subpopulations. The percentage of CD177pos neutrophils remains stable within an individual in physiological conditions. In women, the size of HNA-2pos neutrophils is higher than in men [13]. Also, pregnancy and the administration of GCSF enhance the proportion of HNA-2pos neutrophils [11].

**The CD177 gene**

CD177 gene located on chromosome 19 contains 9 exons and two UTRs and coding for a protein of 437 amino acids that carries the HNA-2 antigen. HNA-2 was originally identified in a case of neonatal neutropenia by Lalzeri et al. [1]. The coding sequence of CD177 was later isolated from granulocytes of polycythemia patients and named PRV1 [14]. Shortly thereafter, in an independent work, Kissel and colleagues identified neutrophil-specific mRNA, named NB1 or HNA-2, which is highly homologous to PRV1 and is only different in sequences at positions 3, 119, 323 and 379; this suggested PRV1 as the allele for NB1 [15]. The CD177 gene is located on chromosome 19q13.31, where a pseudogene harbouring exons 4-9 was also identified in the telomeric region on the anti-sense strand [16].

Frame-shift mutations in CD177 and the insertion of intronic sequences that creates a premature stop codon in CD177 coding region have been considered as responsible mechanism for the absence of the protein on the surface of neutrophils in two women who have children with neonatal alloimmune neutropenia [17].

While several studies have analysed the molecular mechanism of CD177 regulation, the precise mechanism of CD177 expression is still unclear. However, several SNPs have been attributed to the regulation of CD177 expression on the neutrophil surface in different individuals [2,16,18]. Recently, the c.787A>T polymorphism (rs879198465) in CD177, which results in a premature stop codon, has been shown either in combination with c.997delG (compound heterozygote) or alone (homozygote) to be responsible for the absence of CD177 in HNA-2null individuals [19]. The c.787A>T polymorphism resulted from a gene conversion of exon 7 from the CD177 pseudogene into the CD177 gene [20]. However, multiple studies have shown the c.787A>T variant in the heterozygous state in HNA-2null individuals. Since the wild-type allele in c.787A>T heterozygous individuals is expected to be translated into the full protein, the absence of the CD177 protein in such individuals provides evidence for the presence of a complementary mechanism in addition to the c.787A>T SNP contributing to the regulation of CD177 expression [21].

Another polymorphism, c.1291G>A in exon 9 of the CD177 gene, has been associated with the absence of CD177 protein in c.787A>T heterozygous individuals, as well as in those with the atypical expression of the HNA-2 antigen on the neutrophil surface (three peaks: one negative and two positive peaks). In this study, the 787A-1291A (AA) haplotype could lead to low levels and/or the absence of HNA-2 expression in human subjects [22].

CD177 contains a short stretch of hydrophobic amino acids that forms the GPI signal. The polymorphism c.1291G>A (Gly431Arg) is located within the carboxy-terminal hydrophobic region of CD177. The amino acid change from glycine to arginine may affect the
hydrophobicity of CD177 GPI signal, leading to the destabi-
lation of the CD177 protein from the neutrophil sur-
face [22].

DNA methylation has been considered as an epigenetic regulatory mechanism for CD177 expression in physio-
logical and pathological conditions [23]. Polymorphism in 
the promoter region or in the transcription factor binding 
sites has also been considered the reason for the absence of 
CD177 on the CD177\textsubscript{neg} neutrophil subpopulation [18]. A recent study using the HeLa cell model showed an 
association of the CD177\textsubscript{neg} fraction with CpG methyla-
tion in the CD177 regulatory promoter that causes silenc-
ing of the CD177 allele and leads to the monoallelic expression of CD177 [24].

In contrast, our recent analysis using sorted CD177\textsubscript{neg} 
and CD177\textsubscript{pos} neutrophils from a CD177-positive pheno-
typed donor revealed the presence of CD177 mRNA in 
both neutrophil subpopulations, indicating the presence of an active CD177 gene in both neutrophil subpopula-

tions, regardless of the CD177 phenotype. The sequenc-
ing of CD177 mRNA showed identical sequences in 
both subpopulations, rejecting gene silencing as the 
mechanism.

All together, these data suggest the unre vealed multi-

genetic factor mechanism for the regulation of CD177 
expression on the surface of CD177\textsubscript{pos} and CD177\textsubscript{neg} neutrophils.

HNA-2 antibodies

Autoimmune neutropenia is known as the most frequent neutropenia in children. Autoantibodies against HNAs 
have been demonstrated in young children with chronic 
neutropenia [25]. CD177 autoantibodies are also involved in 
immune neutropenia cases [26]. The exposure of 
CD177\textsubscript{null} individuals to CD177-positive pheno-
typed donor revealed the presence of CD177 mRNA in 
both neutrophil subpopulations, indicating the presence of a 
active CD177 gene in both neutrophil subpopulations, 
regardless of the CD177 phenotype. The sequenc-
ing of CD177 mRNA showed identical sequences in 
both subpopulations, rejecting gene silencing as the 
mechanism.

All together, these data suggest the unrevealed multi-
genetic factor mechanism for the regulation of CD177 
expression on the surface of CD177\textsubscript{pos} and CD177\textsubscript{neg} neutrophils.

HNA-2 antibodies

Autoimmune neutropenia is known as the most frequent 
neutropenia in children. Autoantibodies against HNAs have been demonstrated in young children with chronic 
neutropenia [25]. CD177 autoantibodies are also involved in 
immune neutropenia cases [26]. The exposure of 
CD177\textsubscript{null} individuals to CD177-positive cells during pregnancy, transfusion or transplantation induces 
immunization and consequently the production of anti-CD177 
isoantibodies. The passive transfer of anti-CD177 isoantibodies from the mother through the placenta and sensitiz-
ation of fetal neutrophils can cause the destruction of fetal neutrophils, resulting in neonatal alloimmune neutropenia (NAIN) [26]. Isoantibodies against CD177 have been identified in cases of TRALI [27,28]. In an ex vivo rat lung model, isoantibodies against CD177 were able to induce neutrophil activation and the production of reactive oxygen species (ROS) dependent on the density of the cognate antigen on the neutrophil surface [4]. Activated neutrophils have been considered to be responsible for endothelial barrier damage and consequently lung edema [4]. However, multiple observations questioned the role of neutrophils as a sole inducer of lung injury implicated in TRALI [29–32]. How the CD177 isoantibodies affect the function of cells other than neutrophils and participate in the mechanism of TRALI remains unsolved.

HNA-2 interactions

The function of CD177 on neutrophils is mainly unknown. PR3 docking on the surface of neutrophils is largely mediated by CD177 [2,31]. Anti-PR3 in patients with antineutrophil cytoplasmic antibodies (ANCAs) selectively binds CD177-positive neutrophils and induces neutrophil activation and degranulation (Fig. 1) [9]. Residue substitution of PR3 revealed a non-conserved hydrophobic patch (amino acids: 166, 218, 219 and 223) on PR3 as the docking site of this molecule on CD177. Conformational distortion of these hydrophobic patches triggers the rapid solubilization of PR3 and removal from the surface of CD177-transfected cells [8].

The analysis of lipid rafts and immunoprecipitation demonstrated the co-localization of CD177/PR3 with \( \beta_2 \) integrins, principally Mac-1 (CD11b/CD18), which mediates the transduction of signals initiated by anti-PR3 antibodies in the neutrophil cytoplasm [9]. The binding of antibodies against CD11b and CD18 inhibits neutrophil activation triggered by anti-PR3 antibodies [9] (Fig. 1).

![Fig. 1](image-url) In cis interaction, CD177 mediates membrane expression of PR3 and interacts with CD11b/CD18 and FcRIIib (HNA-1b) on the neutrophil surface. The interaction of CD177 with CD11b/CD18 supports transduc-
sion of signals triggers with antibodies that bind CD177/PR3 complex. In trans-interaction, CD177/PR3 complex interact with PECAM-1 immune globulin domain 6 on the endothelial surface.
CD177 has been known as a heterophilic ligand for platelet cell adhesion molecule 1 (PECAM-1), a member of the immune globulin superfamily [4,33]. PECAM-1 immune globulin domain 6 mediates the interaction of CD177 with PECAM-1 on the endothelial surface. The in vitro interaction of CD177-positive neutrophils induces PECAM-1 dephosphorylation and endothelial junction instability that supports neutrophil migration [5]. Accordingly, CD177 ligation with the anti-CD177 antibody (MEM166) efficiently blocks the migration of CD177-positive neutrophils through the endothelial monolayer in a two-compartment chamber [4]. In contrast to the in vitro results, no migratory prevalence of CD177-positive over CD177-negative neutrophils was observed in vivo; CD177-positive and CD177-negative cells migrate equally to inflamed joints, the peritoneum and the oral cavity [34]. These controversial results introduce a complex role for CD177 in different pathways orchestrating the interactions of neutrophils with other cells in vivo.

This effect has been recently correlated with the dynamic co-operation between CD177 and Mac-1, which mediates β2-dependent signalling and orchestrates a set of mechanisms and impairs neutrophil migration [34], therefore enhancing neutrophil adhesion to endothelial cells [35].

In serology analysis of anti-HNA-2 sera, the cross-reactivity of anti-HNA-2 isoantibodies with the immobilized HNA-1b (FcγRIIib) antigen in an antigen-capture assay has been observed (personal communications). Our study, using stable transfected cell expressing HNA-2 or HNA-1b in MAIGA, revealed the presence of only anti-HNA-2 in these sera, suggesting the possibility that CD177 undergoes cis-interaction with FcγRIIib on the neutrophil surface as a mechanism responsible for false-positive reactivity of the serum containing anti-HNA-2 isoantibodies in HNA-1b MAIGA (Fig. 2). Such interactions on the neutrophil surface may lead to false-positive detection of anti-HNA-1b alloantibodies in antigen-capture assays such as the MAIGA.

**Conclusion**

The regulation of CD177 protein expression on the neutrophil surface follows a complex mechanism. At the gene level, nucleotide polymorphisms in the coding region of the CD177 gene lead to the production of a truncated protein or alterations of the GPI-anchor sequence. In HNA-2null individuals, these polymorphisms alone or in combination lead to the absence of the protein from the neutrophil surface and consequently HNA-2null phenotype.

CD177 interacts with the partner proteins in two ways, cis and trans. In the cis-interaction with CD177, PR3 is presented on the neutrophil surface. The cis-interaction of CD177 with CD11b/CD18 conducts the signals initiated by the binding of antibodies to PR3 or the CD177/PR3 complex, towards the neutrophil cytoplasm, and therefore induce neutrophil activation and degranulation. The trans-interaction of CD177 with PECAM-1 mediates cross-talk between neutrophils and endothelial cells implicated during neutrophil transmigration.

The transcription products of the CD177 gene on the neutrophil surface may serve as target in neutrophil specific therapeutic strategies. Moreover, CD177 interactions may be of relevance to suppress neutrophil activation in pathological conditions such as vasculitis.

**Conflict of interests**

The author declares no conflict of interests.

**References**

1. Lalezari P, Murphy GB, Allen FH Jr: NB1, a new neutrophil-specific antigen involved in the pathogenesis of neonatal neutropenia. J Clin Invest 1971; 50:1108–1115
2. Moritz E, Norcia AM, Cardone JD, et al.: Human neutrophil alloantigens systems. An Acad Bras Cien 2009; 81:559–569
3. Hu N, Mora-Jensen H, Theilgaard-Mønch K, et al.: Differential expression of granulopoiesis related genes in neutrophil subsets distinguished by membrane expression of CD177. PLoS One 2014; 9:e99671
Sachs UJ, Andrei-Selmer CL, Maniar A, et al.: The neutrophil-specific antigen CD177 is a counter-receptor for platelet endothelial cell adhesion molecule-1 (CD62). J Biol Chem 2007; 282:23603–23612

Bayat B, Werth S, Sachs UJ, et al.: Neutrophil transmigration mediated by the neutrophil-specific antigen CD177 is influenced by the endothelial S536N dimorphism of platelet endothelial cell adhesion molecule-1. J Immunol 2010; 184:3889–3896

von Vietinghoff VS, Tunnemann G, Eulenberg C, et al.: The nonconservative CD177 single-nucleotide polymorphism c.1291G>A is a genetic determinant for human neutrophil antigen-2 atypical/low expression and deficiency. Transfusion 2019; 59: 1836–1842

Jelinek J, Li, Majoyan Z, et al.: Epigenetic control of PRV-1 expression on neutrophils. Exp Hematol 2007; 35:1677–1683

Eulenberg-Gustavus C, Bähring S, Maass PG, et al.: Gene silencing and a novel monoallelic expression pattern in distinct CD177 neutrophil subsets. J Exp Med 2017; 214:2089–2101

Lalezari P, Khorshidi M, Petrosova M: Autoimmune neutropenia of infancy. J Pediatr 1986; 109:764–769

Bux J, Jung KD, Kauth T, et al.: Serological and clinical aspects of granulocyte antibodies leading to alloimmune neonatal neutropenia. Transfus Med 1992; 2:143–149

Leger R, Palm S, Wulf H, et al.: Transfusion-related lung injury with leukopenic reaction caused by fresh frozen plasma containing anti-NB1. Anesthesiology 1999; 91:1529–1532

Bux J, Becker F, Seeger W, et al.: Transfusion-related acute lung injury due to HLA-A2-specific antibodies in recipient and NB1-specific antibodies in donor blood. Br J Haematol 1996; 93:707–713

Danielson C, Benjamin RJ, Mangano MM, et al.: Pulmonary pathology of rapidly fatal transfusion-related acute lung injury reveals minimal evidence of diffuse alveolar damage or alveolar granulocyte infiltration. Transfusion 2008; 48:2401–2408

Finlayson J, Grey D, Kavanagh L, et al.: Transfusion-related acute lung injury in a neutropenic patient. Intern Med J 2011; 41:638–641

Jerne K, Marino SF, Daumke O, et al.: Characterization of the CD177 interaction with the ANCA antigen proteinase 3. Sci Rep 2017; 7:43328–43338

Bayat B, Tjahjono Y, Sydakov A, et al.: Anti-human neutrophil antigen-3a induced transfusion-related acute lung injury in mice by direct disturbance of lung endothelial cells. Arterioscler Thromb Vasc Biol 2013; 33:2538–2548

Kuckeburg CJ, Tilkens SB, Santos, et al.: Proteinase 3 contributes to transendothelial migration of NB1-positive neutrophils. J Immunol 2012; 188:2419–2426

Strait RT, Hicks W, Barasa N, et al.: MHC class I-specific antibody binding to nonhematopoietic cells drives complement activation to induce transfusion-related acute lung injury in mice. J Exp Med 2011; 208:2525–2544

Bai M, Grieshaber-Bouyer R, Wang J, et al.: CD177 modulates human neutrophil migration through activation-mediated integrin and chemoreceptor regulation. Blood. 2017; 130: 2092–2100